Home > Products > CD3 & VEGFR2
> Human Anti-CD3 x Anti-VEGFR2 Bispecific Antibody (IgG-IgG)
Human Anti-CD3 x Anti-VEGFR2 Bispecific Antibody (IgG-IgG) (CAT#: BSIG-H283)
Anti-CD3 x Anti-VEGFR2 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD3 and anti-VEGFR2 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Colorectal cancer (CRC); Non-small cell lung cancer (NSCLC); Glioblastoma therapy.
CD3 (Cluster of differentiation 3), originally known as T3, is one of the first groups of human T lymphocyte surface antigens recognized by monoclonal antibodies. It has been reported that antibodies against CD3 could either stimulate T cells to divide or inhibit the progress of effector functions according to the conditions used. It plays an important role in T cell and the CD3 T-cell co-receptor helps to activate the cytotoxic T-Cell and T helper cells. The CD3 molecule is composed of a protein complex and consists of four distinct chains. The complex of mammals contains a CD3γ chain, a CD3δ chain, and two CD3ε chains. All these chains associate with T-cell receptor and the ζ-chain to generate an activation signal in T lymphocytes.
There are currently no customer reviews or questions for Human Anti-CD3 x Anti-VEGFR2 Bispecific Antibody (IgG-IgG) (BSIG-H283). Click the button below to contact us or submit your feedback about this product.